Navigation Links
Parent Project Muscular Dystrophy Awards $750,000 Grant to Sildenafil/Taladafil Study

HACKENSACK, N.J., April 4, 2011 /PRNewswire-USNewswire/ -- Parent Project Muscular Dystrophy (PPMD) – the largest, most comprehensive  non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy (Duchenne) – announced today that they will award Ronald G. Victor, M.D. of Cedars-Sinai Medical Center, a $750,000 grant to fund his study of phosphodiesterase inhibitors (sildenafil and taladafil) as a possible therapy for Duchenne.


Dr. Victor and his team at the Cedars-Sinai Heart Institute in Los Angeles discovered a defect in muscle blood flow in mdx mice and boys with Duchenne. Correcting this defect with phosphodiesterase inhibitors (sildenafil and taladafil) improves muscle and heart function in mdx mice. Dr. Victor will conduct a clinical research study to determine if these drugs can improve muscle blood flow in boys with Duchenne, with plans to continue on to a larger multi-center clinical outcomes trial examining both heart and muscle function.

PPMD President and CEO Pat Furlong said that the organization is pleased to support the work of Dr. Victor and Cedars-Sinai. "Parent Project Muscular Dystrophy launched a cardiac initiative at the beginning of this year so that potential treatments in Duchenne took into consideration the effect therapies may have on the heart. Dr. Victor and the wonderful people at Cedars-Sinai have not only taken into consideration cardiac issues in Duchenne, but are also combining existing FDA approved drugs for use as a potential therapy. We are excited by the potential benefit of Dr. Victor's work with sildenafil and taladafil, and continue to be grateful that leading institutions around the country, like Cedars-Sinai Medical Center, are working with this community to end Duchenne."

Dr. Victor, who serves as Associate Director of Clinical Research, Director of the Hypertension Center, and Burns and Allen Professor of Medicine at the Cedars-Sinai Heart Institute, said he was excited that his research team had been awarded the $750,000 grant from Parent Project Muscular Dystrophy.

"To work on a project you feel so passionately about for a community you feel so passionately about, is a reward in and of itself," Dr. Victor said.  "But to have an organization as well respected and trusted at an international level, like Parent Project Muscular Dystrophy, to support your work with such a substantial grant is truly overwhelming. I am so grateful to Pat Furlong for the contribution she continues to make to Duchenne research by supporting projects like mine. She inspires the people in our lab to work even harder to find a therapy that will stop the progression of this devastating disorder."  

Ms. Furlong explained that PPMD has a long history of supporting promising therapies and taking risk on research strategies that otherwise might not get the financial backing they need. "The parents that make up the Duchenne community all share one single goal, to end Duchenne. We take our responsibility to our families very seriously: to thoroughly vet and financially support any research project, any therapy that brings us one step closer to this goal. When we announce something like the cardiac initiative that we launched earlier this year, we put our money where our mouth is. This grant to Dr. Victor combined with our recent $250,000 grant to PTC Therapeutics, gives us a total research investment of $1 million in the first quarter of 2011. We will continue to fund hope for young men living with Duchenne, whenever the opportunity presents itself."

For more about Parent Project Muscular Dystrophy's grant program, as well as a comprehensive list of what we are funding, please visit

About Duchenne muscular dystrophy

Duchenne, the most common form of childhood muscular dystrophy, is a progressive and fatal muscle disorder affecting boys and young men that causes the loss of muscle function, wheelchair dependency and a decline in respiratory and cardiac function.  

About Parent Project Muscular Dystrophy

Parent Project Muscular Dystrophy (PPMD) is a national not-for-profit organization founded in 1994 by parents of children with Duchenne and Becker muscular dystrophy.  Our mission is to end Duchenne. We accelerate research, raise our voices in Washington, demand optimal care for all young men, and educate the global community. PPMD is headquartered in Middletown, Ohio with offices in Fort Lee, New Jersey.  For more information, visit

SOURCE Parent Project Muscular Dystrophy
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Book From Siren Interactive Reveals How Parents of Children With Rare Diseases Play Major Roles in Diagnosis and Treatment
2. Parents Continue to Give Cough and Cold Meds to Young Kids, Despite FDA Warnings
3. Parents, Physicians Unite and Declare: State of Emergency
4. PTC Therapeutics and Parent Project Muscular Dystrophy Advance Drug Discovery Program to Improve Heart Function in Duchenne/Becker Muscular Dystrophy Patients
5. State Launches Immunize for Good Marketing Campaign to Remind Parents Immunizations are Safe and the Best Way to Prevent Childhood Illness
6. Med Time Technology, Inc. Teams up with Give A Smile, Inc. to Provide Pill Timer™ Kits and Toys to Children and Parents at the Chris Evert Childrens Hospital of Broward General
7. Parents Bring Federal Lawsuit After Tainted Baby Formula Injures Newborn
8. Vaccine and Medication Safety are Parents Top Research Priorities
9. New Hope in Austin, Texas for Children Dealing with Social, Academic and Behavioral Issues; Austin Brain Balance Achievement Centers Grand Opening to Include Lectures for Parents, Teachers and Health Professionals
10. Formation of Contract Parenteral Drug Development Services Company Announced
11. Gold Standard/Elsevier Offers Timely, Transparent, Reliable Drug Pricing Data, Including Average Wholesale Price (AWP)
Post Your Comments:
(Date:12/1/2015)... 2015   MabVax Therapeutics Holdings, Inc . (OTCQB: ... has filed an Investigational New Drug Application (IND) with ... Company,s lead fully human antibody product HuMab 5B1 as ... to initiate the Phase I clinical trial early in ... The planned Phase I trial will evaluate the ...
(Date:12/1/2015)... FRANCISCO , Dec. 1, 2015  InCarda Therapeutics, ... development and commercialization of therapies for cardiovascular conditions via ... a subsidiary business in Australia . ... trial in Australia in the ... leading investigators and medical centers in Adelaide ...
(Date:12/1/2015)... , Dec. 1, 2015  The migration ... to develop shared care plans that help patients ... care plans will be digitally enabled, incorporate care ... needs and desires. They will also allow all ... patient,s health journey is optimal. That is the ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition has announced ... Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday 2015, a ... including their ability to work and be productive, to do simple daily activities like ...
(Date:12/1/2015)... ... December 02, 2015 , ... ClinicoEconomics and Outcomes Research ... of treatment for osteoporosis ”. , As corresponding author Dr Ankita Modi says ... with osteoporosis. Based on a large US managed care database, women aged 55 ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an ... has filed a discrimination claim against the U.S. Department of Health and Human Services, ... Care Act (ACA) plans are breaking the clause in the law prohibiting the denial ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of the ... named by MedEsthetics magazine as the Best Single Physician Practice in the nation. Dr. ... elite aesthetic physicians honored by the industry publication. , Dr. Vitenas said he ...
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... epidemic in the 1980s we have seen vast improvements in scientific research and ... made significant strides, providing increased hope and relief to those affected by HIV/AIDS. ...
Breaking Medicine News(10 mins):